User-specified RNA transcript

A 'User-specified RNA transcript' is a generic placeholder for a therapeutic target consisting of a specific ribonucleic acid sequence. RNA targets include messenger RNA (mRNA), which encodes proteins, and various non-coding RNAs (ncRNAs) that perform regulatory roles within the cell (Watts and Corey, 2012, Journal of Pathology). Targeting RNA provides a means to influence the expression of 'undruggable' proteins by intervening before translation occurs. Therapeutic modalities such as antisense oligonucleotides (ASOs) can be designed to promote the degradation of a target transcript via RNase H or to modify pre-mRNA splicing to restore protein function. Similarly, RNA interference (RNAi) utilizes siRNAs to achieve highly specific gene knockdown through the RISC complex. Recent advancements have also expanded the field to include small molecules that bind to complex RNA folds, offering new avenues for treating diseases like cancer and viral infections (Warner et al., 2018, Nature Reviews Drug Discovery). As this is a placeholder term, the specific clinical application and safety profile are dependent on the unique sequence and biological context of the transcript in question.

RNA-targeted therapies, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), bind to specific RNA sequences to induce degradation, modulate splicing, or inhibit translation (Crooke et al., 2018, Nature Reviews Drug Discovery). Small molecules can also target RNA secondary structures to interfere with biological functions (Warner et al., 2018, Nature Reviews Drug Discovery).